觀點飛利浦

Philips’ investors can ill-afford another jolt to their nerves
Lex專欄:飛利浦投資者的神經承受不起再次刺激

Investors in the Dutch healthcare conglomerate had until this week been enjoying a restorative patch
直到本週,這家荷蘭醫療集團的投資者一直過得不錯。

Some companies, it seems, receive the benefit of the doubt even if their performance is a little ho-hum. They can, for example, highlight weak Chinese demand and get away with a mere share price ripple. Other stocks take a razor-sharp cut on every lump and bump. 

有些公司似乎即使業績平平也能得到寬容。例如,它們可以強調中國需求疲軟,而只受到股價微小波動的影響。而其他股票則在每一次起伏中都遭受嚴重打擊。

您已閱讀10%(333字),剩餘90%(3074字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×